Recently, Genelex responded to requests by various stakeholders in the personalized and precision medicine industry by creating High Risk PGx Drug Charts, which are available on the YouScript software. By providing these helpful resources when interpreting PGx results with these resources, Genelex hopes to improve the evaluation of drug-drug, drug-gene, and cumulative interactions in real-time.This interactive clinical decision support (CDS) tool analyzes specific patient’s complete drug list and phenotype results, to ensure more predictable patient responses. There are two versions of the chart available through YouScript: one sorted by major drug specialties and the other sorted alphabetically.
As a thought leader in the field of pharmacogenomics, Genelex strives to revolutionize how we can lessen the occurrence of drug side effects. CEO Kristine Ashcraft will be sharing her insights on pharmacogenomics at Arrowhead’s 8th Annual Personalized & Precision Medicine Conference.
For more information on the High Risk PGx Drug Charts, visit: http://genelex.com/blog/new-and-improved-high-risk-pgx-drug-charts/.
Kristine Ashcraft has been a critical part of the leadership team at Genelex since 2000, and has served many roles since then. Ashcraft’s presentation will focus on Genelex’s long-standing commitment to precision medicine and pharmacogenomics, and two critical questions: who do we test, and how do we do it?
Included in the High Risk PGx Charts are drug-gene pairs, the worst-case-scenario impact rating for the interaction, and any other available guidelines from a variety of organizations who developed dosing guidelines around the world.